Developer docs
API playgroundTry for free, no card

Search company profiles

Collplant

Full company profile

uuid0002ngq

Namestring
Collplant
Legal namestring
CollPlant Biotechnologies Ltd.
Websiteurl
collplant.com
Company typeenum
Public
Founded yearint
2004
Descriptiontext

CollPlant Biotechnologies Ltd. is a publicly traded regenerative medicine company (NASDAQ: CLGN; TASE: CLPT) headquartered in Rehovot, Israel, founded in 2004 and focused on medical aesthetics, tissue regeneration, and 3D bioprinting. Its core technology is recombinant human type I collagen (rhCollagen) produced in genetically engineered tobacco plants using proprietary plant-based genetic engineering; the company states that no competitors produce collagen from plants or recombinant type I human collagen at commercial scale. This single raw-material platform is vertically integrated into commercial products (Collage rhCollagen, the Collink.3D bioink line including the 50, 50L, and 90 variants, the BioFlex ready-to-print DLP kit launched February 2026, and Vergenix STR soft tissue repair matrix) and a development pipeline comprising photocurable dermal fillers and regenerative breast implants.

The company earns revenue from product sales of rhCollagen and bioinks to biopharma companies and academic/research institutions via direct sales, a U.S.-based cGMP logistics center (operational Q4 2025) serving U.S. and Canada, and expanded European distribution. A second revenue stream has historically come from development milestone payments and licensing royalties under the AbbVie/Allergan agreement, which delivered $26M total between 2021 and 2025 but was terminated by AbbVie in April 2026. Following termination, CollPlant is pursuing independent strategic partnerships for its photocurable dermal filler and regenerative breast implant programs and has executed ~50% workforce reduction to extend cash runway into Q4 2026; management has disclosed substantial doubt about the company's ability to continue as a going concern.

For 2025, GAAP revenue was $2.4M (versus $515K in 2024) and GAAP net loss was $11.5M; cash and equivalents stood at $5.6M at year-end with an accumulated deficit of $124.8M. The company holds an extensive patent portfolio (granted in the U.S., South Korea, and Japan) covering rhCollagen, bioinks, and dermal filler formulations through 2038-2039.

Short descriptiontext

CollPlant is a publicly traded regenerative medicine company that produces plant-derived recombinant human type I collagen (rhCollagen) used in its commercial bioink and soft tissue repair products and in pipeline photocurable dermal fillers and regenerative breast implants, serving biopharma firms, academic researchers, and (historically) AbbVie.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRehovot, Israel
HQ citystring
Rehovot
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
recombinant human collagen, 3D bioprinting bioinks, regenerative medicine materials, tissue engineering products, medical aesthetics biomaterials
Industry2 codes
PRIMARYHLAAAGAB
Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAC
3D Bioprinting & Biofabrication
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Regenerative Medicine Materials
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Product Sales (rhCollagen, BioInks, Vergenix STR)
TypeOne Time License
Description

Revenue generated from commercial product sales including rhCollagen (Collage™), bioink products (Collink.3D™), and Vergenix™ STR soft tissue repair matrix. In 2025, product revenues increased driven by rhCollagen product sales and expanded distribution in North America and Europe.

collplant.com
2Development Milestone Payments
TypeLicensing Royalties
Description

One-time payments received upon achievement of development milestones under collaboration agreements. In 2025, CollPlant received a $2 million milestone payment from AbbVie following a development achievement under the dermal filler development agreement. Historically received $10 million (June 2023) and $14 million (February 2021) from AbbVie.

collplant.com
3Licensing and Royalty Revenue
TypeLicensing Royalties
Description

Revenue from granting exclusive licenses to use CollPlant's rhCollagen technology in combination with partners' proprietary technologies for product development and commercialization. CollPlant granted AbbVie a worldwide exclusive license for dermal and soft tissue fillers using rhCollagen combined with AbbVie's technology. Royalty streams expected upon commercialization.

collplant.com
4Registered Direct Offerings (Financing)
TypeOne Time License
Description

Equity financing through registered direct offerings and concurrent private placements. CollPlant completed a $3.6 million offering in May/June 2025 and a $2.0 million offering in February 2026, issuing ordinary shares and warrants. These are financing events rather than revenue-generating operations.

collplant.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Collage™
Description

rhCollagen product derived from plants, bioidentical to native human collagen, offering a safer, purer, and more functional solution than animal-derived collagen.

collplant.com
+3 more records
Core offering1 text field

CollPlant develops, manufactures, and commercializes products derived from proprietary plant-based recombinant human type I collagen (rhCollagen) produced in genetically engineered tobacco plants. Its commercial portfolio includes the Collage rhCollagen raw material, the Collink.3D bioink platform (50, 50L, 90 variants), the BioFlex ready-to-print DLP bioprinting kit, and the Vergenix STR soft tissue repair matrix for tendinopathy. Its development pipeline includes photocurable regenerative dermal fillers and regenerative breast implants for medical aesthetics and reconstructive applications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Collink.3D™ bioink demonstrated superior structured tissue formation compared to Matrigel® in a comparative study, supporting its value as a consistent, tunable, animal-free alternative for advanced tissue engineering.
+3 more records
Product overview1 text field

CollPlant develops regenerative medicine products based on recombinant human collagen (rhCollagen) produced through proprietary plant-based genetic engineering technology. The product portfolio includes: Collage™ as the foundational rhCollagen raw material; the Collink.3D™ bioink platform (including 50, 50L, and 90 variants) for 3D bioprinting applications; BioFlex as a ready-to-print DLP bioprinting kit; and Vergenix™ STR for soft tissue repair. The development pipeline includes photocurable dermal fillers and regenerative breast implants. The technology enables tissue engineering, regenerative medicine, drug discovery, and organ manufacturing applications.

Product and service8 records
1Collage (rhCollagen)
CategoryRecombinant collagen raw material
Description

Plant-derived recombinant human type I collagen that is bioidentical to native human collagen, offering a safer, purer, and more functional solution than animal-derived collagen for tissue regeneration applications. Targeted at biopharma companies and academic/research institutions.

2Collink.3D 50
Category3D bioprinting bioink
Description

rhCollagen-based bioink designed for 3D bioprinting applications with tunable rheological properties, biocompatibility, and optimal performance at room temperature, enabling precise mimicry of human tissue physical characteristics for tissue regeneration research.

3Collink.3D 50L
Category3D bioprinting bioink
Description

rhCollagen-based bioink variant for 3D bioprinting with enhanced properties tailored for specific tissue engineering applications.

4Collink.3D 90
Category3D bioprinting bioink
Description

rhCollagen-based bioink variant designed for 3D bioprinting applications requiring specific mechanical properties for tissue regeneration.

5BioFlex
Category3D bioprinting bioink kit
Description

Ready-to-print rhCollagen-based bioink kit for DLP 3D bioprinting that integrates Collink.3D 50 with proprietary photoactive agents, enabling researchers and industry partners to produce customized, high-performance bioinks with tunable mechanical properties for tissue engineering and regenerative medicine applications without the complexity of multi-component formulation.

6Vergenix STR
CategorySoft tissue repair matrix
Description

Advanced soft tissue repair matrix of recombinant human collagen (rhCollagen) combined with autologous Platelet-Rich Plasma (PRP), indicated for the treatment of tendinopathy affecting approximately 2% of the general population and over 40% of sports-related injuries.

7Dermal Fillers (Pipeline)
CategoryMedical aesthetics (pipeline)
Description

Pipeline rhCollagen-based photocurable dermal and soft tissue filler combining rhCollagen with hyaluronic acid to provide skin lifting, tissue regeneration, and contouring abilities for facial volume restoration, midface deflation, jawline definition loss, skin laxity, and weight-loss-associated facial changes; currently in preclinical development.

8Regenerative Breast Implants (Pipeline)
CategoryMedical aesthetics (pipeline)
Description

Pipeline regenerative breast implants comprised of proprietary rhCollagen and biomaterials, designed to promote tissue regeneration and degrade in synchronization with newly grown tissue for aesthetic and reconstructive procedures including post-mastectomy breast reconstruction, addressing complications of conventional implants.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1U.S.-Based Logistics Center
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-10-01
Description

Partnership with a U.S.-based logistics center providing full cGMP-compliant storage and distribution services and clinical supply depot for rhCollagen and BioInk products in the U.S. and Canada. Operational in Q4 2025, this partnership expanded CollPlant's distribution footprint into North America to support growing commercial presence.

collplant.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-10-01
Description

Mayo Clinic researchers used CollPlant's plant-derived rhCollagen to develop the first fully humanized 3D bioprinted human skin model. Results published in Archives of Dermatological Research. The model combines rhCollagen with key human skin cell types, providing an innovative alternative to animal testing for preclinical research in cosmetics, pharmaceuticals, and disease modeling.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-02-01
Description

Development and global commercialization agreement for dermal and soft tissue filler products using CollPlant's rhCollagen technology in combination with AbbVie's proprietary technologies. AbbVie was granted a worldwide exclusive license. AbbVie conducted clinical trials initiated in 2023. CollPlant received $2M milestone (Feb 2025), $10M (June 2023), and $14M (Feb 2021). The agreement was terminated by AbbVie in April 2026 following a 5-year collaboration.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Aspect Biosystems
TypeEmerging player
Description

Aspect Biosystems develops 3D bioprinted tissue therapeutics using proprietary bioink and bioprinting technology, overlapping with CollPlant's mission to biofabricate functional human tissues using collagen-based bioinks.

TypeBroad incumbent
Description

Organogenesis is an established regenerative medicine company selling skin substitutes and wound-care biologics (e.g., Apligraf), directly comparable to CollPlant's regenerative soft tissue repair and skin/breast tissue programs.

TypeEmerging player
Description

FibroGen develops therapeutics based on connective tissue growth factors and recombinant collagen technologies, with adjacent applications in tissue regeneration and aesthetics overlapping with CollPlant's rhCollagen platform.

TypeBroad incumbent
Description

Galderma is a leading aesthetics company (Restylane, Sculptra, etc.) that competes in the dermal filler and regenerative aesthetics market where CollPlant's photocurable rhCollagen filler is positioned, especially for GLP-1-related facial volume loss.

TypeBroad incumbent
Description

MTF Biologics provides tissue grafts and regenerative biologics for breast reconstruction, sports medicine, and wound care, overlapping with CollPlant's Vergenix STR and regenerative breast implant programs.

6Advanced BioMatrix
TypeDirect peer
Description

Advanced BioMatrix supplies collagen-based bioinks (including type I collagen) and 3D bioprinting reagents, directly competing with CollPlant's Collink.3D bioink line for academic and biopharma tissue engineering customers.

TypeDirect peer
Description

Organovo is a pioneering 3D bioprinting company developing functional human tissues for therapeutic and research applications, directly comparable to CollPlant in the 3D bioprinting / regenerative tissue engineering category.

TypeDirect peer
Description

Humabiologics produces human-derived and recombinant collagen and other extracellular matrix proteins for regenerative medicine and 3D bioprinting, positioning it as a direct competitor to CollPlant's plant-derived rhCollagen platform.

TypeBroad incumbent
Description

Integra LifeSciences is a large medical device company with regenerative technology portfolios including dermal regeneration templates and wound-care matrices, competing in overlapping surgical and regenerative categories with CollPlant's breast implant and soft tissue repair programs.

TypeDirect peer
Description

BICO (formerly CELLINK) is the leading commercial supplier of bioinks and 3D bioprinting consumables, including collagen-based bioinks, and directly competes with CollPlant's Collink.3D and BioFlex product lines for the same biopharma and academic customers.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds14 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Collplant

Regenerative Medicine Materialscollplant.com

CollPlant is a publicly traded regenerative medicine company that produces plant-derived recombinant human type I collagen (rhCollagen) used in its commercial bioink and soft tissue repair products and in pipeline photocurable dermal fillers and regenerative breast implants, serving biopharma firms, academic researchers, and (historically) AbbVie.

What Collplant does

CollPlant Biotechnologies Ltd. is a publicly traded regenerative medicine company (NASDAQ: CLGN; TASE: CLPT) headquartered in Rehovot, Israel, founded in 2004 and focused on medical aesthetics, tissue regeneration, and 3D bioprinting. Its core technology is recombinant human type I collagen (rhCollagen) produced in genetically engineered tobacco plants using proprietary plant-based genetic engineering; the company states that no competitors produce collagen from plants or recombinant type I human collagen at commercial scale. This single raw-material platform is vertically integrated into commercial products (Collage rhCollagen, the Collink.3D bioink line including the 50, 50L, and 90 variants, the BioFlex ready-to-print DLP kit launched February 2026, and Vergenix STR soft tissue repair matrix) and a development pipeline comprising photocurable dermal fillers and regenerative breast implants.

The company earns revenue from product sales of rhCollagen and bioinks to biopharma companies and academic/research institutions via direct sales, a U.S.-based cGMP logistics center (operational Q4 2025) serving U.S. and Canada, and expanded European distribution. A second revenue stream has historically come from development milestone payments and licensing royalties under the AbbVie/Allergan agreement, which delivered $26M total between 2021 and 2025 but was terminated by AbbVie in April 2026. Following termination, CollPlant is pursuing independent strategic partnerships for its photocurable dermal filler and regenerative breast implant programs and has executed ~50% workforce reduction to extend cash runway into Q4 2026; management has disclosed substantial doubt about the company's ability to continue as a going concern.

For 2025, GAAP revenue was $2.4M (versus $515K in 2024) and GAAP net loss was $11.5M; cash and equivalents stood at $5.6M at year-end with an accumulated deficit of $124.8M. The company holds an extensive patent portfolio (granted in the U.S., South Korea, and Japan) covering rhCollagen, bioinks, and dermal filler formulations through 2038-2039.

Collplant firmographics

Firmographics
Name
Collplant
Legal name
CollPlant Biotechnologies Ltd.
Website
https://collplant.com
Company type
Public
Founded year
2004
Operating status
Operating
Headcount range
11–50 employees
Short description
CollPlant is a publicly traded regenerative medicine company that produces plant-derived recombinant human type I collagen (rhCollagen) used in its commercial bioink and soft tissue repair products and in pipeline photocurable dermal fillers and regenerative breast implants, serving biopharma firms, academic researchers, and (historically) AbbVie.
Ownership category
akta.pro rank

Collplant industry classification

Industry
Product category
Regenerative Medicine Materials
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAAAGAB
Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAC
3D Bioprinting & Biofabrication
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Recombinant human collagen
  • 3D bioprinting bioinks
  • Regenerative medicine materials
  • Tissue engineering products
  • Medical aesthetics biomaterials

Where Collplant is headquartered

Location

Headquarters

HQ city
Rehovot
HQ country
Israel
HQ region
Middle East

Offices1 record

Markets served

Collplant business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Product Sales (rhCollagen, BioInks, Vergenix STR): Revenue generated from commercial product sales including rhCollagen (Collage™), bioink products (Collink.3D™), and Vergenix™ STR soft tissue repair matrix. In 2025, product revenues increased driven by rhCollagen product sales and expanded distribution in North America and Europe.
  2. Development Milestone Payments: One-time payments received upon achievement of development milestones under collaboration agreements. In 2025, CollPlant received a $2 million milestone payment from AbbVie following a development achievement under the dermal filler development agreement. Historically received $10 million (June 2023) and $14 million (February 2021) from AbbVie.
  3. Licensing and Royalty Revenue: Revenue from granting exclusive licenses to use CollPlant's rhCollagen technology in combination with partners' proprietary technologies for product development and commercialization. CollPlant granted AbbVie a worldwide exclusive license for dermal and soft tissue fillers using rhCollagen combined with AbbVie's technology. Royalty streams expected upon commercialization.
  4. Registered Direct Offerings (Financing): Equity financing through registered direct offerings and concurrent private placements. CollPlant completed a $3.6 million offering in May/June 2025 and a $2.0 million offering in February 2026, issuing ordinary shares and warrants. These are financing events rather than revenue-generating operations.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels7 records

Collplant product offering

Product offering

Core offering

CollPlant develops, manufactures, and commercializes products derived from proprietary plant-based recombinant human type I collagen (rhCollagen) produced in genetically engineered tobacco plants. Its commercial portfolio includes the Collage rhCollagen raw material, the Collink.3D bioink platform (50, 50L, 90 variants), the BioFlex ready-to-print DLP bioprinting kit, and the Vergenix STR soft tissue repair matrix for tendinopathy. Its development pipeline includes photocurable regenerative dermal fillers and regenerative breast implants for medical aesthetics and reconstructive applications.

Product overview

CollPlant develops regenerative medicine products based on recombinant human collagen (rhCollagen) produced through proprietary plant-based genetic engineering technology. The product portfolio includes: Collage™ as the foundational rhCollagen raw material; the Collink.3D™ bioink platform (including 50, 50L, and 90 variants) for 3D bioprinting applications; BioFlex as a ready-to-print DLP bioprinting kit; and Vergenix™ STR for soft tissue repair. The development pipeline includes photocurable dermal fillers and regenerative breast implants. The technology enables tissue engineering, regenerative medicine, drug discovery, and organ manufacturing applications.

Differentiator

Problem solved

Functional benefit

Brands

  • Collage™: rhCollagen product derived from plants, bioidentical to native human collagen, offering a safer, purer, and more functional solution than animal-derived collagen.
  • Collink.3D™
  • Vergenix™ STR
  • BioFlex

Products and services

  • Collage (rhCollagen) Plant-derived recombinant human type I collagen that is bioidentical to native human collagen, offering a safer, purer, and more functional solution than animal-derived collagen for tissue regeneration applications. Targeted at biopharma companies and academic/research institutions.
  • Collink.3D 50 rhCollagen-based bioink designed for 3D bioprinting applications with tunable rheological properties, biocompatibility, and optimal performance at room temperature, enabling precise mimicry of human tissue physical characteristics for tissue regeneration research.
  • Collink.3D 50L rhCollagen-based bioink variant for 3D bioprinting with enhanced properties tailored for specific tissue engineering applications.
  • Collink.3D 90 rhCollagen-based bioink variant designed for 3D bioprinting applications requiring specific mechanical properties for tissue regeneration.
  • BioFlex Ready-to-print rhCollagen-based bioink kit for DLP 3D bioprinting that integrates Collink.3D 50 with proprietary photoactive agents, enabling researchers and industry partners to produce customized, high-performance bioinks with tunable mechanical properties for tissue engineering and regenerative medicine applications without the complexity of multi-component formulation.
  • Vergenix STR Advanced soft tissue repair matrix of recombinant human collagen (rhCollagen) combined with autologous Platelet-Rich Plasma (PRP), indicated for the treatment of tendinopathy affecting approximately 2% of the general population and over 40% of sports-related injuries.
  • Dermal Fillers (Pipeline) Pipeline rhCollagen-based photocurable dermal and soft tissue filler combining rhCollagen with hyaluronic acid to provide skin lifting, tissue regeneration, and contouring abilities for facial volume restoration, midface deflation, jawline definition loss, skin laxity, and weight-loss-associated facial changes; currently in preclinical development.
  • Regenerative Breast Implants (Pipeline) Pipeline regenerative breast implants comprised of proprietary rhCollagen and biomaterials, designed to promote tissue regeneration and degrade in synchronization with newly grown tissue for aesthetic and reconstructive procedures including post-mastectomy breast reconstruction, addressing complications of conventional implants.

Quantifiable outcome

  • Collink.3D™ bioink demonstrated superior structured tissue formation compared to Matrigel® in a comparative study, supporting its value as a consistent, tunable, animal-free alternative for advanced tissue engineering.
  • +3 more outcomes

Companies that use Collplant

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Collplant technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Collplant partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • U.S.-Based Logistics CentercoreChannel Partner/ Reseller/ Distributor · 1 October 2025Partnership with a U.S.-based logistics center providing full cGMP-compliant storage and distribution services and clinical supply depot for rhCollagen and BioInk products in the U.S. and Canada. Operational in Q4 2025, this partnership expanded CollPlant's distribution footprint into North America to support growing commercial presence.
  • Mayo ClinicminorStrategic or Co-development Partner · 1 October 2025Mayo Clinic researchers used CollPlant's plant-derived rhCollagen to develop the first fully humanized 3D bioprinted human skin model. Results published in Archives of Dermatological Research. The model combines rhCollagen with key human skin cell types, providing an innovative alternative to animal testing for preclinical research in cosmetics, pharmaceuticals, and disease modeling.
  • AbbVie / Allergan Industrie SAScoreStrategic or Co-development Partner · 1 February 2021Development and global commercialization agreement for dermal and soft tissue filler products using CollPlant's rhCollagen technology in combination with AbbVie's proprietary technologies. AbbVie was granted a worldwide exclusive license. AbbVie conducted clinical trials initiated in 2023. CollPlant received $2M milestone (Feb 2025), $10M (June 2023), and $14M (Feb 2021). The agreement was terminated by AbbVie in April 2026 following a 5-year collaboration.

Scale indicators13 records

Recent moves8 records

Expansion highlights6 records

Collplant competitors and assessment

Company assessment

Emerging players

  • Aspect Biosystems: Aspect Biosystems develops 3D bioprinted tissue therapeutics using proprietary bioink and bioprinting technology, overlapping with CollPlant's mission to biofabricate functional human tissues using collagen-based bioinks.
  • FibroGen: FibroGen develops therapeutics based on connective tissue growth factors and recombinant collagen technologies, with adjacent applications in tissue regeneration and aesthetics overlapping with CollPlant's rhCollagen platform.

Broad incumbents

  • Organogenesis: Organogenesis is an established regenerative medicine company selling skin substitutes and wound-care biologics (e.g., Apligraf), directly comparable to CollPlant's regenerative soft tissue repair and skin/breast tissue programs.
  • Galderma: Galderma is a leading aesthetics company (Restylane, Sculptra, etc.) that competes in the dermal filler and regenerative aesthetics market where CollPlant's photocurable rhCollagen filler is positioned, especially for GLP-1-related facial volume loss.
  • MTF Biologics: MTF Biologics provides tissue grafts and regenerative biologics for breast reconstruction, sports medicine, and wound care, overlapping with CollPlant's Vergenix STR and regenerative breast implant programs.
  • Integra LifeSciences: Integra LifeSciences is a large medical device company with regenerative technology portfolios including dermal regeneration templates and wound-care matrices, competing in overlapping surgical and regenerative categories with CollPlant's breast implant and soft tissue repair programs.

Direct peers

  • Advanced BioMatrix: Advanced BioMatrix supplies collagen-based bioinks (including type I collagen) and 3D bioprinting reagents, directly competing with CollPlant's Collink.3D bioink line for academic and biopharma tissue engineering customers.
  • Organovo: Organovo is a pioneering 3D bioprinting company developing functional human tissues for therapeutic and research applications, directly comparable to CollPlant in the 3D bioprinting / regenerative tissue engineering category.
  • Humabiologics: Humabiologics produces human-derived and recombinant collagen and other extracellular matrix proteins for regenerative medicine and 3D bioprinting, positioning it as a direct competitor to CollPlant's plant-derived rhCollagen platform.
  • BICO / CELLINK: BICO (formerly CELLINK) is the leading commercial supplier of bioinks and 3D bioprinting consumables, including collagen-based bioinks, and directly competes with CollPlant's Collink.3D and BioFlex product lines for the same biopharma and academic customers.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights5 records

Customer concentration

Collplant social profiles

Digital presence

Collplant financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Collplant leadership team

Management profile

Number of profiles

Profiles9 records

Collplant subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Collplant funding detail

Funding detail

Funding overview

Funding rounds14 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Collplant M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Collplant

What does Collplant do?

CollPlant develops, manufactures, and commercializes products derived from proprietary plant-based recombinant human type I collagen (rhCollagen) produced in genetically engineered tobacco plants. Its commercial portfolio includes the Collage rhCollagen raw material, the Collink.3D bioink platform (50, 50L, 90 variants), the BioFlex ready-to-print DLP bioprinting kit, and the Vergenix STR soft tissue repair matrix for tendinopathy. Its development pipeline includes photocurable regenerative dermal fillers and regenerative breast implants for medical aesthetics and reconstructive applications.

Is Collplant a public or private company?

Collplant is a public company. It is classified as public and is currently operating.

When was Collplant founded?

Collplant was founded in 2004. It employs 11 to 50 people.

Where is Collplant based?

Collplant is headquartered in Rehovot, Israel, in the Middle East region.

How does Collplant make money?

Four revenue lines are on record. Product Sales (rhCollagen, BioInks, Vergenix STR) is the primary driver. The others are development Milestone Payments, licensing and Royalty Revenue and registered Direct Offerings (Financing).

Who are Collplant's main competitors?

Emerging players on record are Aspect Biosystems and FibroGen. Broad incumbents are Organogenesis, Galderma, MTF Biologics and Integra LifeSciences. Direct peers are Advanced BioMatrix, Organovo, Humabiologics and BICO / CELLINK.

Does Collplant have an API?

No public API is recorded for Collplant.

What industry is Collplant in?

Collplant's product category is Regenerative Medicine Materials. Its primary akta.pro industry code is HLAAAGAB, Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials), with a secondary code of HLAAAGAC, 3D Bioprinting & Biofabrication. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialCollplant To Begin Trading On Nasdaq Under New Ticker Symbol“OPHI”CollPlant Biotechnologies will begin trading on Nasdaq under the new ticker symbol OPHI on November 13, 2026, with CLGN trading until November 12. The company plans to change its name to OptiPhi Computing Ltd. subject to shareholder approval at a meeting on November 24, 2026.Stock TitanCollPlant to change Nasdaq ticker to OPHI Nov. 13CollPlant Biotechnologies will begin trading on Nasdaq under the new ticker symbol OPHI on November 13, 2026, with shares continuing under CLGN through November 12. The company plans to change its name to OptiPhi Computing Ltd., subject to shareholder approval at its extraordinary general meeting on November 24, 2026.The future of tradingCollPlant Seeks Shareholder Approval for Name Change to OptiPhi ComputingCollPlant Biotechnologies shareholders will vote on a board-backed proposal to rename the company OptiPhi Computing at the November 24, 2026, meeting. The proposed name reflects expansion into photonic computing following the acquisition of LightSolver in September 2026, and a Nasdaq ticker change from CLGN to OPHI is planned, subject to Nasdaq confirmation.American Banking and Market NewsAnalyzing CollPlant Biotechnologies (NASDAQ:CLGN) and uniQure (NASDAQ:QURE)A comparison of uniQure and CollPlant Biotechnologies evaluates profitability, analyst ratings, and valuation. CollPlant Biotechnologies has a higher consensus price target ($120 vs $53.25) and lower institutional ownership, while uniQure beats on 9 of 14 factors. Analysts favor CollPlant due to its higher probable upside.Markets DailyContrasting CollPlant Biotechnologies (NASDAQ:CLGN) & CureVac (NASDAQ:CVAC)CureVac and CollPlant Biotechnologies are compared on dividends, valuation, analyst ratings, risk, institutional ownership, profitability, and earnings. CureVac beats CollPlant on 8 of 12 factors, with higher revenue and earnings, though CollPlant trades at a lower P/E. Analysts rate CollPlant more favorably with a consensus target price of $120.Markets DailyAnalyzing CollPlant Biotechnologies (NASDAQ:CLGN) and CareDx (NASDAQ:CDNA)CareDx and CollPlant Biotechnologies are compared on earnings, analyst ratings, profitability, risk, valuation, and institutional ownership. CollPlant has a higher consensus price target ($120 vs $54) and lower beta, but CareDx beats on 10 of 14 factors. Analysts favor CollPlant due to its higher probable upside.MarketScreenerCollPlant Biotechnologies Ltd. announced that it expects to receive $3.699986 million in fundingCollPlant Biotechnologies entered into definitive agreements for a private placement of 989,301 ordinary shares at $3.74 each, raising gross proceeds of $3,699,985.74. The company also issued unregistered warrants to purchase up to 1,483,952 shares at $3.74, exercisable immediately and expiring five years after registration. The placement is expected to close on or about October 14, 2026.Third NewsCollPlant Secures $3.7 Million in Private Placement to Boost Technology DevelopmentCollPlant Biotechnologies agreed to a $3.7 million private placement of 989,301 shares and warrants, priced at $3.74 per share. The funds will accelerate LightSolver's laser-based supercomputing and LPU technology, with closing expected around October 14, 2026.American Banking and Market NewsAnalyzing CollPlant Biotechnologies (NASDAQ:CLGN) and CareDx (NASDAQ:CDNA)CareDx and CollPlant Biotechnologies are compared on risk, valuation, profitability, and analyst ratings. CollPlant has a higher upside potential (3,216.75% vs 21.08%) and lower P/E, but CareDx beats on 11 of 15 factors. Analysts favor CollPlant due to its higher probable upside.Investing.comCollplant ADR earnings beat by $0.56, revenue fell short of estimatesCollplant ADR reported Q3 EPS of -$1.89, beating the analyst estimate of -$2.45 by $0.56, but revenue of $108K fell short of the $480K consensus. The stock closed at $3.78, up 11.11% over three months and down 84.63% over a year.